Document Type : Systematic Reviews


Department of Nutrition, Science and Research Branch, Islamic Azad University, Tehran, Iran


One of the most worldwide chronic diseases is diabetes which has affected a large population worldwide and it is predicted that 649 million adults will be diabetic by 2040. Many foods and ingredients were tested to combat diabetes. Both probiotics and prebiotics which are known as synbiotic have shown beneficial effects on many diseases including diabetes. Although several studies have evaluated the effect of synbiotic consumption on lipid profile in patients with diabetes, findings are inconsistent. The aim of this study was to evaluate the effects of synbiotics on lipid profile in diabetic patients. A systematic literature search of online databases including PubMed, Scopus, Google Scholar, Magiran, SID, and Cochrane’s library was conducted up to January 2021. Randomized controlled trials (RCTs) investigating the effects of synbiotics on lipid profile in diabetic patients were included. A total of 11 RCTs with 662 participants were included. Synbiotic consumption resulted in a decrease in plasma concentrations of TC, TG, LDL, and an increase in plasma HDL levels compared to the control group (placebo supplements/control foods/conventional products). Synbiotic supplements may be profitable to ameliorate lipid profile in patients with diabetes and it should be suggested by both dietitians and healthcare clinics to diabetic patients.


1. American Diabetes Association. Diagnosis and classification of diabetes mellitus. Diabetes Care. 2010;33(1): 62–9.
2. WHO. World Health Organization: Health topics, Diabetes. 2014.
3. IDF. International Diabetes Federation: IDF Diabetes Atlas. 2015.
4. Forbes JM, Cooper ME. Mechanisms of diabetic complications. Physiological Reviews. 2013;93(1):137-88.
5. Larsen N, Vogensen FK, van den Berg FW, Nielsen DS, Andreasen AS, Pedersen BK, et al. Gut microbiota in human adults with type 2 diabetes differs from non-diabetic adults. PLoS One 2010;5(2): e9085.
6. Musso G, Gambino R, Cassader M. Obesity, diabetes, and gut microbiota: the hygiene hypothesis expanded?. Diabetes Care. 2010;33(10):2277-84.
7. Ejtahed HS, Soroush AR, Angoorani P, Larijani B, Hasani-Ranjbar S. Gut microbiota as a target in the pathogenesis of metabolic disorders: A new approach to novel therapeutic agents. Hormone and Metabolic Research. 2016;48(6):349-58.
8. Kechagia M, Basoulis D, Konstantopoulou S, Dimitriadi D, Gyftopoulou K, Skarmoutsou N, et al. Health benefits of probiotics: a review. ISRN Nutrition 2013;2013:481651.
9. Vergin, F. Antibiotics and probiotics. Hipokrates. 1954;25:116–9.
10.  Food and Agriculture Organization of the United Nations, issuing body. World Health Organization, issuing body. Probiotics in food: health and nutritional properties and guidelines for evaluation.
11.  Markowiak P, Slizewska K. Effects of Probiotics, Prebiotics, and Synbiotics on Human Health. Nutrients. 2017;9(9):1021.
12.  Moroti C, Magri LFS, de Rezende Costa M, Cavallini DC, Sivieri K. Effect of the consumption of a new symbiotic shake on glycemia and cholesterol levels in elderly people with type 2 diabetes mellitus. Lipids in Health and Disease. 2012;11(1):29.
13.  Kavitha K, Reddy AG, Reddy KK, Kumar CS, Boobalan G, Jayakanth K. Hypoglycemic, hypolipidemic and antioxidant effects of pioglitazone, insulin and synbiotic in diabetic rats. Veterinary World. 2016;9(2):118.
14.  Rajkumar H, Kumar M, Das N, Kumar SN, Challa HR, Nagpal R. Effect of probiotic Lactobacillus salivarius UBL S22 and prebiotic fructo-oligosaccharide on serum lipids, inflammatory markers, insulin sensitivity, and gut bacteria in healthy young volunteers: a randomized controlled single-blind pilot study. Journal of Cardiovascular Pharmacology and Therapeutics. 2015;20(3):289–98.
15.  Asemi Z, Khorrami-Rad A, Alizadeh S-A, Shakeri H, Esmaillzadeh A. Effects of synbiotic food consumption on metabolic status of diabetic patients: a double-blind randomized cross-over controlled clinical trial. Clinical Nutrition. 2014;33(2):198–203.
16.  Nikbakht E, Khalesi S, Singh I, Williams LT, West NP, Colson N. Effect of probiotics and synbiotics on blood glucose: a systematic review and meta-analysis of controlled trials. European Journal of Nutrition. 2018;57(1):95–106.
17.  Eslamparast T, Zamani F, Hekmatdoost A, et al. Effects of synbiotic supplementation on insulin resistance in subjects with the metabolic syndrome: a randomised, double-blind, placebo-controlled pilot study. British Journal of Nutrition. 2014;112(3):438–45.
18.  Tajadadi-Ebrahimi M, Bahmani F, Shakeri H, et al. Effects of daily consumption of synbiotic bread on insulin metabolism and serum high-sensitivity C-reactive protein among diabetic patients: a double-blind, randomized, controlled clinical trial. Annals of Nutrition and Metabolism. 2014;65(1):34–41.
19.  Shakeri H, Hadaegh H, Abedi F, Tajabadi-Ebrahimi M, Mazroii N, Ghandi Y, Asemi Z. Consumption of synbiotic bread decreases triacylglycerol and VLDL levels while increasing HDL levels in serum from patients with type-2 diabetes. Lipids. 2014;49(7):695–701.
20.  Asemi Z, Alizadeh S-A, Khorshidi A, Goli M, Esmaillzadeh A. Effects of beta-carotene fortified synbiotic food on metabolic control of patients with type 2 diabetes mellitus: A double-blind randomized cross-over controlled clinical trial. Clinical Nutrition. 2016;35(4):819-25.
21.  Ahmadi S, Jamilian M, Tajadadi-Ebrahimi M, Jafari P, Asemi Z. The effects of synbiotic supplementation on markers of insulin metabolism and lipid profiles in gestational diabetes: a randomised, double-blind, placebo-controlled trial. British Journal of Nutrition. 2016;116:1394–401.
22.  Tajabadi-Ebrahimi M, Sharifi N, Farrokhian A, Raygan F, Karamali F, Razzaghi R, Taheri S, Asemi Z. A randomized controlled clinical trial investigating the effect of synbiotic administration on markers of insulin metabolism and lipid profiles in overweight type 2 diabetic patients with coronary heart disease. Experimental and Clinical Endocrinology & Diabetes. 2016;125(01):21–7.
23.  Ebrahimi Z, Nasli-Esfahani E, Nadjarzade A, Mozaffarikhosravi H. Effect of symbiotic supplementation on glycemic control, lipid profiles and microalbuminuria in patients with non-obese type 2 diabetes: a randomized, double-blind, clinical trial. Journal of Diabetes & Metabolic Disorders. 2017;16(1):23.
24.  Razmpoosh E, Javadi A, Ejtahed HS, Mirmiran P, Javadi M, Yousefinejad A, The effect of probiotic supplementation on glycemic control and lipid profile in patients with type 2 diabetes: A randomized placebo-controlled trial. Diabetes & Metabolic Syndrome: Clinical Research & Reviews. 2019;13(1):175-82.
25.  Nabhani Z, Hezaveh S.J.G, Razmpoosh E, Asghari-Jafarabadi M, Gargari B. The effects of synbiotic supplementation on insulin resistance/sensitivity, lipid profile and total antioxidant capacity in women with gestational diabetes mellitus: a randomized double-blind placebo-controlled clinical trial. Diabetes Research and Clinical Practice. 2018;138:149-57.
26.  Soleimani A, Motamedzadeh A, Mojarrad MZ, Bahmani F, Amirani E, Ostadmohammadi V, Tajabadi-Ebrahimi M, Asemi Z. The effects of synbiotic supplementation on metabolic status in diabetic patients undergoing hemodialysis: A randomized, double-Blinded, placebo-controlled trial. Probiotics and Antimicrobial Proteins. 2019;11(4):1248–56.
27.  Zare Javid A, Aminzadeh M, Haghighi-zadeh M.H, Jamalvandi M. The Effects of synbiotic supplementation on glycemic status, lipid profile, and biomarkers of oxidative stress in type 1 diabetic patients: A placebo-controlled, double-blind, randomized clinical trial. Diabetes, Metabolic Syndrome and Obesity: Targets and Therapy. 2020;13: 607–17.
28.  Mohammadi H, Miraghajani M, Ghaedi E. Efficacy of synbiotic supplementation in patients with nonalcoholic fatty liver disease: a systematic review and meta-analysis of clinical trials: Synbiotic supplementation and NAFLD. Critical Reviews in Food Science and Nutrition. 2019;59(15):2494-505.
29.  De Vrese M, Schrezenmeir AJ. Probiotics, prebiotics, and synbiotics.  Advances in Biochemical Engineering / Biotechnology. 2008;111:1-66.           
30.  Konstantinov SR, Smidt H, de Vos WM, Bruijns SC, Singh SK, Valence F, Molle D, Lortal S, Altermann E, Klaenhammer TR, Van Kooyk Y (2008) S layer protein A of Lactobacillus acidophilus NCFM regulates immature dendritic cell and T cell functions. Proceedings of the National Academy of Sciences of the United States of America. 2008;105(49):19474–79.
31.  Ouwehand AC, Tiihonen K, Saarinen M, Putaala H, Rautonen N. Influence of a combination of Lactobacillus acidophilus NCFM and lactitol on healthy elderly: intestinal and immune parameters. British Journal of Nutrition. 2008;101(3):367–75.
32.  Brubaker SW, Bonham KS, Zanoni I, Kagan JC. Innate immune pattern recognition: a cell biological perspective. Annual Review of Immunology. 2015;33:257–90.
33.  Dasu MR, Devaraj S, Park S, Jialal I. Increased toll-like receptor (TLR) activation and TLR ligands in recently diagnosed type 2 diabetic subjects. Diabetes Care. 2010;33(4):861–68.
34.  Kimoto H, Ohmomo S, Okamoto T. Cholesterol removal from media by Lactococci. Journal of Dairy Science. 2002;85(12):3182–3188.
35.  Lye H-S, Rusul G, Liong M-T. Removal of cholesterol by Lactobacilli via incorporation and conversion to coprostanol. J Dairy Sci. 2010;93(4):1383–92.
36.  Begley M, Hill C, Gahan CG. Bile salt hydrolase activity in probiotics. Applied and Environmental Microbiology. 2006;72(3):1729–38.
37.  Patel AK, Singhania RR, Pandey A, Chincholkar SB. Probiotic bile salt hydrolase: current developments and perspectives. Applied Biochemistry and Biotechnology. 2010;162(1):166–80. 
38.  De Preter V, Vanhoutte T, Huys G, Swings J, De Vuyst L, Rutgeerts P, Verbeke K. Effects of Lactobacillus casei Shirota, Bifidobacterium breve, and oligofructose-enriched inulin on colonic nitrogen-protein metabolism in healthy humans. American Journal of Physiology-Gastrointestinal and Liver Physiology. 2007;292(1):358–68.
39.  Zhuang G, Liu X-M, Zhang Q-X, Tian F-W, Zhang H, Zhang H-P, Chen W. Research advances with regards to clinical outcome and potential mechanisms of the cholesterol-lowering effects of probiotics. Journal of Clinical Lipidology. 2012;7(5):501–7.
40.  Leung C, Rivera L, Furness JB, Angus PW. The role of the gut microbiota in NAFLD. Nature Reviews Gastroenterology & Hepatology. 2016;13(7):412.
41.  Lee J, Hong S-W, Rhee E-J, Lee W-Y. GLP-1 receptor agonist and non-alcoholic fatty liver disease. Diabetes & Metabolism Journal. 2012;36(4):262–7.
42.  Campbell JE, Drucker DJ (2013) Pharmacology, physiology, and mechanisms of incretin hormone action. Cell Metabolism. 2013;17(6):819–837.
43.  Wojdemann M, Wettergren A, Sternby B, Holst JJ, Larsen S, Rehfeld JF, Olsen O. Inhibition of human gastric lipase secretion by glucagon-like peptide-1. Digestive Diseases and Sciences. 1998;43(4):799–05.